文献速递MDS 与骨髓增殖性肿瘤白血病

地西他滨治疗高危慢性粒单核细胞白血病的II期多中心试验

A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia.
PubMed 文献 · Leukemia · 2017-06-13

这项前瞻性II期意大利研究纳入43例高危慢性粒单核细胞白血病(CMML)患者,给予地西他滨20 mg/m2/日,每28天周期第1-5天静脉给药。意向治疗人群(n=42)中,6周期后总缓解率为47.6%,中位随访51.5个月,中位总生存17个月,缓解者生存显著长于未缓解者(P=0.02)。

要点

  • 地西他滨20 mg/m2/日,每28天周期第1-5天静脉给药,治疗高危CMML。
  • 6周期后总缓解率47.6%,完全缓解率16.6%。
  • 中位随访51.5个月,中位总生存17个月,缓解者生存显著优于未缓解者(P=0.02)。

核心结论

  • 地西他滨似为高危CMML患者有效且耐受性良好的治疗。

研究设计与样本

  • 前瞻性II期意大利多中心研究,43例CMML患者入组,意向治疗人群n=42。

主要发现

  • 意向治疗人群(n=42)6周期后总缓解率为47.6%,其中完全缓解7例(16.6%),骨髓缓解8例(19%),部分缓解1例(2.4%),血液学改善4例(9.5%)。
  • 中位随访51.5个月(范围44.4-57.2),中位总生存17个月,缓解者生存显著长于未缓解者(P=0.02)。
  • 3/4级贫血、中性粒细胞减少和血小板减少分别发生于28.6%、50%和38%的患者。
  • 入组患者中超过50%根据四种CMML专用评分系统属于高危。

关键数值与推荐

  • 地西他滨给药方案:20 mg/m2/日,每28天周期第1-5天静脉给药。
  • 疗效于第4和第6周期后评估,6周期末缓解者可继续地西他滨治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic myelomonocytic leukemia (CMML) is a complex clonal hematological disorder classified among myelodysplastic (MDS)/myeloproliferative neoplasms. Prognosis is poor and there is a lack of effective treatments. The hypomethylating agent decitabine has shown activity against MDS and elderly acute myeloid leukemia, but there is little data focusing specifically on its efficacy in CMML. In this prospective, phase 2 Italian study, CMML patients received intravenous decitabine 20 mg/m2 per day on Days 1-5 of a 28-day treatment cycle. Response was evaluated after four and six cycles; patients responding at the end of six cycles could continue treatment with decitabine. Forty-three patients were enrolled; >50% were high-risk according to four CMML-specific scoring systems. In the intent-to-treat population (n=42), the overall response rate after six cycles was 47.6%, with seven complete responses (16.6%), eight marrow responses (19%), one partial response (2.4%) and four hematological improvements (9.5%). After a median follow-up of 51.5 months (range: 44.4-57.2), median overall survival was 17 months, with responders having a significantly longer survival than non-responders (P=0.02). Grade 3/4 anemia, neutropenia and thrombocytopenia occurred in 28.6%, 50% and 38% of patients, respectively. Decitabine appears to be an effective and well-tolerated treatment for patients with high-risk CMML.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Santini V, Allione B, Zini G, et al. A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia. Leukemia. 2017. PMID: 28607470. doi:10.1038/leu.2017.186

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。